9-ME-BC

Status Not approved for human use; no registered human trialBest evidence E4Sources checked 2026-09-18

9-Me-BC is a German-developed beta-carboline small molecule, not a peptide, studied in cell culture and rodents for dopaminergic neuron protection and regeneration as a candidate Parkinson’s treatment. No human trial exists, and it inhibits monoamine oxidase, a drug class with known interaction risks that have not been characterised for this molecule in people.

What it is

9-Methyl-beta-carboline (9-Me-BC) is a small synthetic molecule in the beta-carboline (pyridoindole) family, developed and studied largely by a German research group centered at the Technical University of Dresden (Polanski, Gille, Reichmann and colleagues). It is not a peptide. Beta-carbolines as a class include both toxic and protective members; 9-Me-BC is specifically studied as a candidate with stimulatory and protective effects on dopaminergic neurons, positioning it as a potential Parkinson’s disease treatment.

What has actually been tested

Published research describes 9-Me-BC increasing tyrosine hydroxylase expression and neurite outgrowth in dopaminergic neurons, inhibiting monoamine oxidase A and B (with an IC50 of about 1 micromolar for MAO-A and 15.5 micromolar for MAO-B in one cell-culture study), and stimulating astrocytes to express neurotrophic factors including BDNF, through a mechanism reported to run via the organic cation transporter and the PI3K signalling pathway. These findings come from cultured dopaminergic and cortical astrocyte cell lines and from rodent studies; no human trial was located for this entry.

No registered clinical trial of 9-Me-BC, for Parkinson’s disease or any other indication, appears on ClinicalTrials.gov.

What is not known

Whether 9-Me-BC’s dopaminergic-neuron-protective and MAO-inhibiting effects, established in cell culture and rodent models, reproduce in a human being with Parkinson’s disease or any other condition. No human trial exists.

Human pharmacokinetics, human dosing, and human safety, including interactions relevant to a compound that inhibits monoamine oxidase, a drug class with well-known interaction risks (notably with other serotonergic or dopaminergic agents) that has not been characterised for this specific molecule in people.

Whether 9-Me-BC’s reported benefits can be separated from the toxic effects associated with other members of the beta-carboline family it belongs to.

What is not known

Whether 9-Me-BC’s dopaminergic-neuron effects, shown in cell culture and rodents, reproduce in a human being. No human trial exists.

Human pharmacokinetics, dosing and safety, including monoamine-oxidase-inhibitor interaction risks that have not been characterised for this specific molecule in people.

Whether its reported benefits can be separated from the toxicity associated with other beta-carbolines.

Doses used in published research

No published study has administered this compound to a human being, so no dose appears in the literature and none has been established.

Amounts above record what a named source reported administering in a study. They are not a recommendation, not a protocol, and not instructions.

Converting a vial and a syringe into a draw volume is a separate, mechanical question from what amount to use. The reconstitution calculator does that arithmetic for peptide, HCG, and HGH vials.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported use	Route	Amount reported	Frequency	Reported length
Neuroprotective/dopaminergic support, general	Oral	Varies by listing	Varies by listing	Varies by listing

Circulating listings for 9-Me-BC describe oral capsule or powder use at doses that vary by seller. There is no human trial of any kind to check that figure against; the published research for this compound is limited to cultured cells and rodents, none of which reported a dose in a form comparable to a per-capsule human figure.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.